Corcept Therapeutics Beats Q2 Estimates, Cuts Guidance and Advances NDA for New Cancer Drug

Core Insights - Corcept Therapeutics Incorporated (NASDAQ:CORT) is recognized as one of the 12 stocks with consistent growth potential for investment [1] - The company reported a strong Q2 performance but subsequently lowered its full-year revenue guidance [2] Financial Performance - In Q2 2025, Corcept achieved an EPS of $0.29, surpassing estimates by 45% compared to the expected $0.20 [2] - Revenue for the quarter was $194.4 million, reflecting an 18.7% year-over-year increase [2] - The company has revised its full-year revenue guidance to a range of $850 million to $900 million [2] Drug Development and Regulatory Updates - The FDA has accepted the New Drug Application (NDA) for Corcept's drug candidate, Relacorilant, aimed at treating platinum-resistant ovarian cancer [3] - A decision date for the NDA has been set for July 11, 2026, which is expected to de-risk a significant portion of the company's pipeline [3] - Corcept plans to present new data from the pivotal Phase 3 ROSELLA trial at the European Society for Medical Oncology (ESMO) annual meeting on October 19, 2025 [3] Company Overview - Corcept Therapeutics has demonstrated a remarkable 10-year performance increase of 1534.68%, indicating a strong market position [4] - Founded in 1998, the company focuses on developing drugs for severe metabolic, psychiatric, and oncologic disorders by modulating cortisol effects [4]